NeoVanc: New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis
2021
NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted.
🇬🇧 NeoVanc: New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis
2021
Padova – Italy, November 27th 2021
NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted:
- No clear benefit was seen with the use of an optimised short (5±1 day) course of vancomycin,
World Sepsis Day
2020
The 13th September marks World Sepsis Day. Infectious diseases remains a leading cause of death for children. The burden of this problem is particularly felt in sub-Saharan Africa and in Central and Southern Asia,
ISF/ESCMID Sepsis Award 2020
2020
Aislinn Cook, a research fellow at St. George’s University of London in the Paediatric Infectious Diseases Research Group, is the winner of the ISF/ESCMID Sepsis Award 2020!